Accession Number:

ADA555934

Title:

Hormonal Resistance And Metastasis ER-Coregulartor-Src Signaling Targeted Therapy

Descriptive Note:

Annual rept. 1 Sep 2010-31 Aug 2011

Corporate Author:

TEXAS UNIV AT SAN ANTONIO HEALTH SCIENCE CENTER

Personal Author(s):

Report Date:

2011-09-01

Pagination or Media Count:

56.0

Abstract:

The estrogen receptor ER is implicated in the progression of breast cancer. Despite positive effects of hormonal therapy, initial or acquired resistance to endocrine therapies frequently occurs. To establish the significance of ER-Src axis in PELP1 and HER2 mediated therapy resistance, we have generated model cells that stably express Src-shRNA under conditions of PELP1, HER2 deregulation. Depletion of Src using shRNA substantially reduced E2 mediated activation of Src and MAPK activation in resistant model cells. Pharmacological inhibition of Src using dasatinib, an orally available inhibitor substantially inhibited the growth of therapy resistant MCF7-PELP1, MCF7-HER2, and MCF7-Tam model cells in proliferation assays. In post-menopausal xenograft based studies, treatment with dasatinib significantly inhibited the growth of therapy resistant cells. Since PELP1, HER2, and Src kinase are commonly deregulated in breast cancers, combination therapies using both endocrine agents and dasatinib may have better therapeutic effect by delaying the development of hormonal resistance.

Subject Categories:

  • Anatomy and Physiology
  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE